<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02953873</url>
  </required_header>
  <id_info>
    <org_study_id>00061221</org_study_id>
    <nct_id>NCT02953873</nct_id>
  </id_info>
  <brief_title>Dosing Requirements of Astagraf XL® in African American Kidney Transplant Recipients</brief_title>
  <official_title>Dosing Requirements of Astagraf XL® in African American Kidney Transplant Recipients Converted From Twice-daily Tacrolimus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of South Carolina</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Compare the difference in dose-normalized trough and total daily dose necessary to reach the
      steady state therapeutic goal after conversion from tacrolimus IR to Astagraf XL® in African
      American kidney transplant recipients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to compare the difference in medication dosage and total daily
      dose necessary of Astagraf XL® in order to reach therapy goal, when taken with other
      medications that are routinely used for kidney transplantation, which may stop the
      development of a substance that can cause long-term damage to the transplanted kidney.
      African American kidney transplant patients aged 18 and above who are underwent a kidney
      transplant are eligible to participate. The duration of the study is 3 months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 5, 2017</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>dose-normalized trough</measure>
    <time_frame>Baseline to 3 months post-conversion</time_frame>
    <description>Difference in dose-normalized trough at steady state before and after conversion from tacrolimus IR to Astagraf XL® by CYP3A5 expressers versus non-expressers</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference in Total Daily Dose</measure>
    <time_frame>Baseline to 3 months post conversion</time_frame>
    <description>Difference in TDD necessary for steady state therapeutic goal by CYP3A5 expressers vs non-expressers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Daily Dose Ratio</measure>
    <time_frame>Baseline to 3 months post conversion</time_frame>
    <description>Total Daily Dose Ratio necessary to reach steady state therapeutic goal between CYP3A5 expressers vs. non-expressers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients</measure>
    <time_frame>Baseline to 3 months post conversion</time_frame>
    <description>Proportion of patients with a Total Daily Dose Ratio of 1mg:1mg by CYP3A5 expressers vs non-expressers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight-Based Dose</measure>
    <time_frame>Baseline to 3 months post conversion</time_frame>
    <description>Weight-based dose requirements to reach therapeutic goal pre- and post-conversion by CYP3A5 expressers vs. non-expressers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days to reach goal</measure>
    <time_frame>Baseline to 3 months post conversion</time_frame>
    <description>Days to reach therapeutic goal after conversion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose Modifications</measure>
    <time_frame>Baseline to 3 months post conversion</time_frame>
    <description>Number of dose modifications in the follow-up period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morisky Medication Adherence Scal</measure>
    <time_frame>Baseline to 3 months post conversion</time_frame>
    <description>Morisky Medication Adherence Scale (MMAS-8) at the time of conversion compared to 90 days after conversion</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Immunosuppression</condition>
  <arm_group>
    <arm_group_label>Conversion Arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Tacrolimus Extended Release Capsule (goal 5 - 12ng/mL) + Mycophenolate Mofetil ≥500mg twice a day OR Mycophenolate Sodium ≥360mg twice a day+ prednisone ≥ 5mg Daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus Extended Release Capsule</intervention_name>
    <description>goal trough 5 - 12ng/mL</description>
    <arm_group_label>Conversion Arm</arm_group_label>
    <other_name>Astagraf XL</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate mofetil</intervention_name>
    <description>≥500mg twice a day</description>
    <arm_group_label>Conversion Arm</arm_group_label>
    <other_name>Cellcept</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>goal dose 5mg daily</description>
    <arm_group_label>Conversion Arm</arm_group_label>
    <other_name>Corticosteroids</other_name>
    <other_name>Methylprednisolone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate Sodium</intervention_name>
    <description>≥360mg twice a day</description>
    <arm_group_label>Conversion Arm</arm_group_label>
    <other_name>Myfortic</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. At least 18 years of age

          2. Signed informed consent

          3. African American race

          4. History of a solitary renal transplant

          5. Stable tacrolimus dose for at least 2 weeks prior to randomization

        Exclusion Criteria:

          1. A condition or disorder that, in the opinion of the investigator, may adversely affect
             the outcome of the study or the safety of the subject

          2. Currently enrolled in an investigational drug trial

          3. History of a non-renal organ transplant

          4. History of acute cellular rejection within 1 month prior to randomization

          5. An increase in serum creatinine by &gt; 20% in the 2 weeks prior to randomization

          6. Maintenance immunosuppression that does not consist of tacrolimus IR given twice
             daily, mycophenolate mofetil &gt; 1000mg TDD or mycophenolate sodium &gt; 720mg TDD, and
             prednisone ≥ 5mg daily
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Fleming, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medicual U of South Carolina</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mackenzie Fraser</last_name>
    <phone>843-792-8896</phone>
    <email>fraserm@musc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Fleming, PharmD</last_name>
      <phone>843-792-5868</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 2016</study_first_submitted>
  <study_first_submitted_qc>November 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 3, 2016</study_first_posted>
  <last_update_submitted>May 14, 2018</last_update_submitted>
  <last_update_submitted_qc>May 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of South Carolina</investigator_affiliation>
    <investigator_full_name>James N. Fleming</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>The data will not be shared.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

